Assay sensitivity has been proposed as a criterion for including psychiatric clinical outcome studies in meta-analyses. The authors assess the performance of assay sensitivity as a method for determining study appropriateness for meta-analysis by calculating expected standard drug vs placebo e ect sizes for various combinations of high quality and awed studies. In the absence of awed studies, expected e ect sizes are close to unbiased only when sample sizes are very large. In the presence of awed studies, expected e ect sizes tend to be substantially biased except under simultaneous conditions of high power, a large proportion of awed studies, and a population standard vs placebo e ect size of awed studies considerably lower than that of high quality studies. The authors conclude that this method is not robust and can lead to serious bias. Unless it can be shown that speciÿc conditions hold, assay sensitivity should not be used to make quality judgments of studies.
INTRODUCTION
The summary of information from clinical research studies is crucial for health care decisions and public health policy. A meta-analysis combines the quantitative information reported in completed studies into a single estimate of the e ect size of a treatment, usually in comparison to a control condition. (The e ect sizes in this paper indicate comparisons between conditions, rather than change within treatments, unless otherwise noted.) The ability of meta-analysis to contribute to useful health care decisions rests on the ability of reviewers to assess the quality of individual studies, in order to remove, to the extent possible, studies that would systematically bias the e ect size estimate calculated [1] [2] [3] [4] . So far, most of the methods proposed
945
We consider good and bad studies with balanced designs and equal known variances for the three conditions; standard (S), placebo (P), and other (O) treatment. In addition, we assume that the outcome measure X has a normal distribution in all three study arms.
Let S = standard, P = placebo, and O = other treatment. X S , X P , and X O are independent. Let X S ; X P ; X O ∼ N( i ;
2 ) and n = n S = n P = n O , i ∈ {S; P; O}. The population e ect size is ij = ( i − j )= where i; j ∈ {S; P; O}; i = j
The sample estimator of the population e ect size is
Under these assumptions, each d ij follows a normal distribution with mean ij and standard error (2=n) 1=2 , where n is the cell sample size [11] . We assume that the quality of a study only a ects the mean response, so that the probability distributions of the standard vs placebo e ect size estimators from both good and bad studies can be represented by normal distributions with standard errors of (2=n) 1=2 . E ect size estimation involving the third arm of studies will be considered later.
All statistical tests are performed using a two-sided alpha of 0.05.
RESULTS

Model 1: bad studies present; misclassiÿcation absent
In order for the AS method to include all good studies and exclude all bad studies from meta-analysis, the e ect of the standard drug condition must be signiÿcantly greater than the e ect of the placebo condition in all of the good studies and in none of the bad studies. Thus, for all good studies to demonstrate AS, all standard vs placebo e ect sizes must exceed the critical e ect size that cuts o a right tail of area 0.025 on the null sampling distribution (all good studies must be powered to 100 per cent). Similarly, for no bad study to demonstrate AS, no standard vs placebo e ect size from a bad study should exceed that critical e ect size. A situation close to this is shown in Figure 1 , in which the cell sample size is 60, and 99.9 per cent of the good studies demonstrate AS while 0.1 per cent of bad studies demonstrate AS. Achieving this degree of separation of good from bad studies requires a good e ect size of 0.91 and a bad e ect size of −0:19, assumptions that are unrealistic for standard vs placebo comparisons of treatments for psychiatric disorders. The e ect size of 0.91 is considerably larger than the mean e ect size estimates that are typically calculated in meta-analyses of treatments for mood and anxiety disorders [12, 13] , and a negative e ect size for bad studies would mean that in those studies, placebo tends to consistently outperform standard treatment.
A substantial increase in sample size would be required to model more realistic e ect sizes, but larger sample sizes are not commonly found in the literature. In short, the ideal case is unlikely to be a realistic case in the foreseeable future; AS cannot be expected to correctly classify all (or nearly all) good and bad studies. 
Model 2: bad studies absent
In the absence of bad studies, the in uence of AS on the expected standard vs placebo e ect size is determined by the power of a study. Good studies that lack AS exhibit type II error; using the AS method in the absence of bad studies involves excluding good studies due to chance. As power increases, the proportion of good studies that are incorrectly excluded from meta-analysis decreases, and the bias caused by the AS method decreases. Figure 2 depicts power curves for the standard vs placebo di erence for three cell sample sizes that have been commonly used in studies of mood and anxiety disorders [14] [15] [16] . If all the studies under consideration are good, the biasing e ect on the standard vs placebo comparison of excluding non-AS studies is depicted in Figure 3 , in which the normal probability distribution of e ect size estimator d SP is left-truncated at the critical value d 
where (t) is the standard normal probability density function, (t) is the standard normal cumulative distribution function, d
AS SP is a sample estimator of the standard vs placebo e ect size from a study with AS.
The critical value d
CRIT SP is chosen so that d
The mean of the left-truncated distribution is always larger than or equal to the untruncated one, thus E(d
For example, as shown in Figure 3 , the population e ect size of good studies is 0.30, but the estimate calculated from just the studies with AS is 0.48. Figure 4 displays the biased e ect size estimate expectations as a function of the population e ect size for the three sample sizes used in Figure 2 . Only when power is extremely high, and the percentage of excluded studies, therefore, extremely low, is the degree of bias negligible. A cell sample size of 120 and a population e ect size exceeding 0.50, and a cell sample size of 60 and a population e ect size exceeding 0.70, are associated with power ( Figure 2 Drug responsive subpopulations. Each combination of e ect size and sample size is associated with a speciÿc biased e ect size. It is widely recognized [18] [19] [20] that a population su ering from what is deÿned as a single psychiatric disorder can be composed of subpopulations heterogeneous in severity, type, time course of symptoms, or responsiveness to active or placebo treatment. A study demonstrating AS is sometimes described as having enrolled a drug-responsive sample [21, 22] , which could be assumed to represent not the population that meets the inclusion/exclusion criteria of a trial, but a more drug-responsive subset of this population. Drug e ects in this 'subpopulation' would overestimate the e ects in the larger population; conversely, drug e ects in the larger population would underestimate e ects in the subpopulation.
There are several problems with using a sample outcome to deÿne a subpopulation when performing a meta-analysis. One can conceive of a subpopulation of, for example, depressed outpatients, who are more responsive to a drug on average than are depressed outpatients as a whole. The subpopulation might be deÿned a priori by, for example, severity criteria, diagnostic subtype, or (lack of) comorbidity with other disorders. The subpopulation e ect size would be greater than the e ect size of the entire depressed outpatient population. A meta-analyst might be interested in estimating the e ect size of the subpopulation and thus would reasonably exclude studies that did not explicitly sample from the subpopulation. The meta-analytic e ect size would then provide an estimate of the e ect of the treatment in the speciÿed subpopulation.
However, combining e ect size estimates from studies with sample characteristics that are deÿned post hoc from statistical analysis of outcome data, such as the assessment of AS, is another matter. In a population or subpopulation deÿned a priori, a meta-analysis averaging the e ect size estimates from an inÿnite number of studies sampling from the speciÿed population, regardless of the sample size of those studies, will theoretically produce the population e ect size. This is the basis of meta-analysis; a meta-analysis of a ÿnite number of studies of possibly varying sample sizes provides an estimate of the one true population e ect size. When sample characteristics are deÿned post hoc, what does a meta-analysis of studies with AS estimate? Taking the mean of an inÿnite number of studies with AS will, unlike the mean of an a priori subpopulation, result in di erent numerical values depending on the sample sizes of the studies. The values shown in Figure 4 can be interpreted as the results of such meta-analyses. Thus, a meta-analysis of studies with AS that all have the same sample size, for example, 30=cell, will estimate the biased e ect size depicted in Figure 4 ; that is, if the population e ect size is 0.50, the meta-analysis would estimate the biased e ect size of 0.71. If the meta-analysis includes only studies of sample size 60=cell, it will estimate the biased e ect size of 0.57. There is no one true e ect size of a post hoc 'population' for a meta-analysis to estimate. Taking the mean e ect size estimate of AS studies of various sample sizes would result in values that depend on the mix of the sample sizes as well as the true population e ect size; there is no coherent interpretation of the result of such a meta-analysis. Studies cannot be excluded from meta-analyses on the basis of post hoc sampling characteristics such as those deÿned by AS. Subpopulations must be deÿned a priori, and anything that might be considered a sampling problem must be identiÿable independently of outcome results.
Bias in small numbers of trials. Before we consider more complex assumptions, there is another aspect of bias that should be elucidated. The biased e ect sizes shown in Figure 4 were calculated for an inÿnite number of trials. In a ÿnite number, the proportion of studies discarded and the consequent degree of bias can be much higher. For example, for an inÿnite number of good studies powered to 0.78, 22 per cent would be discarded. For ÿve such studies, to discard one study would be already to discard 20 per cent. Using the binomial distribution, we ÿnd that there is a 71 per cent chance that one or more of ÿve studies would be discarded, and a 30 per cent chance that two or more would be discarded, leading to even more bias than shown in Figure 4 . Unless very large sample sizes are employed, and mediumto-large [11] e ect sizes represent reality, using the AS method can lead to substantially biased meta-analytic estimates under these circumstances.
E ect sizes involving the third treatment condition. The AS method uses as a criterion the standard vs placebo e ect size, but not e ect sizes involving the third treatment condition. In addition, the conditions are assumed to be independent. That is, the response of any individual in one of the conditions is assumed not to a ect the response of any individuals in the other two groups. For example, the response of any individual in the placebo condition does not a ect the response of any individual in the standard drug condition or the third condition. Given the lack of contribution of the third treatment condition to the determination of AS, along with the independence of the conditions, the estimate of the within-treatment mean e ect of the third condition is una ected by whether or not the AS method is used. The AS method increases the standard vs placebo e ect size by selecting studies in which, on an average, the within-treatment mean e ect of the standard drug is overestimated and the within-treatment mean e ect of the placebo is underestimated. Under the model assumptions, the contributions to bias come equally from the overestimate of the within-treatment mean e ect of the standard drug condition (from the right tail of the distribution of mean e ects of the standard drug condition) and the underestimate of the within-treatment mean e ect of the placebo condition (from the left tail of the distribution of mean e ects of the placebo condition). That is, the degree to which the mean e ect of the standard drug is overestimated equals the degree to which the mean e ect of the placebo is underestimated. Because the estimate of the mean e ect of the third condition is unbiased, it follows that the bias of the standard vs other treatment equals the bias of the other treatment vs placebo. In other words, in the absence of bad studies, the bias in the e ect size estimates involving the third treatment condition is equal to one-half of the bias in the standard vs placebo e ect size (for a formal approach to this question, see Appendix A).
For example, consider again Figure 3 , in which n=cell is 60, the population standard vs placebo e ect size is 0.30, and the biased standard vs placebo e ect size is 0.48 (a bias of 0.18). If the third treatment condition is equally e ective as the standard (so that its e ect size compared to placebo is also 0.30), the biased e ect size of the third condition vs placebo is 0.39 (a bias of 0.18=2 or 0.09), and the biased e ect size of the standard vs the third condition is 0.09 (the unbiased e ect size is 0.0). In all cases, the third treatment condition's e ect compared to placebo is overestimated, and its e ect compared to the standard drug is underestimated.
Model 3: bad studies present, misclassiÿcation present
We have shown in Model 2 that when all studies are good, the AS method introduces bias into e ect size estimates, and this bias cannot be dismissed by referring to a drug-responsive subpopulation. If all studies are good, there is no need to eliminate studies from meta-analyses, and no possible role for the AS method. However, if AS also excluded bad studies from metaanalyses, the disadvantage of excluding good studies could be outweighed by the beneÿts of excluding bad ones if certain assumptions hold. Although we do not know the population e ect sizes for good and bad studies, we can examine the e ects of the AS method in a number of circumstances, and show what kinds of conditions must be assumed for the AS method to produce unbiased long-run estimates of standard vs placebo e ect sizes.
Considering the presence of bad studies requires taking into account, in addition to the sample size and population e ect size for good studies, the population e ect size for bad studies and the proportion of good and bad studies in the overall population of studies. As in the discussion of good studies alone, the two-sided alpha is 0.05. To minimize the number of ÿgures in this paper, we consider only one sample size: 60=cell. When the sample size is 60=cell and the population e ect size for good studies is 0.50, power is 0.78, close to the 0.80 typically considered adequate [23] . When good study e ect sizes are overestimated, due to overly optimistic estimates resulting from publication bias [23] or other factors, actual power can be lower than nominal power. To take into account both the possibility of adequately and inadequately powered studies, we examine cases in which the sample size is 60=cell, and the population e ect size for good studies is either 0.50 or 0.30 (in the latter case, power is 0.38). We vary the population e ect size of bad studies as well as the proportion of bad and good studies in the population of studies.
The biased estimate, E(d
, of the population e ect size of the standard vs placebo di erence is the mean of a left-truncated mixture probability distribution that is initially composed of the sum of the two normal distributions that represent the distributions of good and bad study e ect sizes. This biased estimate can be calculated as a weighted average of the Figure 5 . Left-truncated mixture distribution depicting the calculation of the long-run e ect size estimate resulting from using the AS method in the presence of good and bad studies. In this case, the cell sample size is 60, the e ect size of good studies is 0:30 a , the e ect size of bad studies is 0.20, and the proportion of bad studies is 50 per cent. The e ect size criterion for AS, d means of the good and bad e ect size distributions left-truncated at the critical value d
CRIT SP , where the weights are the proportions of good and bad studies, respectively, represented in the left-truncated (AS) mixture distribution (see Appendix B). An example of this is depicted in Figure 5 , and the biased estimates are shown in Figure 6 .
In Figure 6 , biased population standard vs placebo e ect size estimates are shown based on using the AS method to exclude studies. As the bad study e ect size increases, more and more bad studies are misclassiÿed as good, and the expected e ect size of AS studies increases, in a concave manner. When the e ect size of bad studies equals the e ect size of good studies, the biased e ect size is the same as when all studies are good; that is, the biased e ect sizes include those shown in Figure 4 . This is true regardless of the proportion of bad studies. For example, when the sample size is 60=cell, and both e ect sizes equal 0.50, the biased e ect size is 0.57 (a bias of 0.07); when both equal 0.30, the biased e ect size is 0.48 (a bias of 0.18). The bias curves pivot about this point, and become steeper as the proportion of bad studies increases. Naturally, upward bias is present when the bad study e ect size equals or surpasses that of the good studies. In some cases when the bad study e ect size is lower than that of the good studies, this bias is reduced so that it is non-existent or negligible, but in other cases, the upward bias is not substantially counterbalanced. In general, the AS method seems to introduce minimal bias when the studies considered for meta-analysis are highly powered, the proportion of bad studies is substantial, and the e ect size of the bad studies is considerably lower than that of the good studies, simultaneously.
E ect sizes involving the third treatment condition. A biased e ect size estimate involving the third treatment condition in the presence of bad studies is a weighted average (similar to that described above) of the biased estimates from the good and bad studies, where the weights are the proportions of good and bad studies, respectively, represented in the left-truncated (AS) mixture distribution (see Appendix B). Consider again Figure 5 , in which n=cell is 60, the population standard vs placebo e ect size for good studies is 0.30, and the population standard vs placebo e ect size for bad studies is 0.20. Assume that the aws in the bad studies do not a ect the relative e ectiveness of the standard and third treatment conditions, and that the third treatment condition is equally e ective as the standard in both good and bad studies (so that its e ect size compared to placebo is 0.30 in good studies and 0.20 in bad studies). The biased placebo vs standard e ect size is 0.47 (a bias of 0.17), the biased e ect size of the third treatment condition vs placebo is 0.37 (a bias of 0.07), and the biased e ect size of the standard vs the third treatment condition is 0.10 (where the unbiased e ect size is 0.0). Unlike the case in the absence of bad studies, in the presence of bad studies the bias in the comparison of the third treatment vs placebo is not necessarily equal to the bias in the comparison of the standard vs the third treatment.
DISCUSSION
At ÿrst glance AS, a metaphor that has been in uential in the context of approving new drugs in the United States, appears to be an attractive, labour-saving alternative or additional criterion to traditional methods for assessing study quality and appropriateness for meta-analysis. However, there are several problems with the AS method. The AS method excludes good studies that exhibit type II error, biasing meta-analytic results in favour of the standard drug. The e ect size estimates from these studies should be included in meta-analyses, because excluding them biases the results. The AS method does not live up to claims that it helps to select patients from subpopulations of interest; valid subpopulations must be deÿned a priori. The AS method, at best, can only help to eliminate bad studies that underestimate the effectiveness of a standard drug, not bad studies that exaggerate the drug's e ectiveness. Even if bad studies tend consistently to underestimate the e ectiveness of a standard drug, under many circumstances using the AS method would still result in a substantially biased e ect size estimate that would overestimate the drug's e ectiveness.
Unless evidence is gathered to support the hypothesis that using the AS method reduces bias, meta-analysts should make quality judgments that are based on study methods, and that are independent of outcome. This means that, depending upon judgments made about each study's methodology, studies demonstrating AS can be excluded from meta-analyses, and studies not demonstrating AS, or not able to demonstrate AS because they do not contain a placebo condition, can be included. The placebo condition retains its importance in determining the e cacy of treatments, but the standard vs placebo comparison does not play a useful role in judging a study's quality.
APPENDIX A: EFFECT SIZE ESTIMATES INVOLVING THIRD TREATMENT ARM IN LEFT-TRUNCATED NORMAL DISTRIBUTION
Let ij and d ij be deÿned as in equations (1) and (2) 
